Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul:285:39-51.
doi: 10.1016/j.ahj.2025.02.007. Epub 2025 Feb 20.

Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial

Nancy Haff  1 , Daniel M Horn  2 , Gauri Bhatkhande  3 , Meekang Sung  4 , Caitlin Colling  5 , Wendy Wood  6 , Ted Robertson  7 , Daniel Gaposchkin  5 , Leigh Simmons  5 , Judy Yang  5 , James Yeh  5 , Katherine L Crum  4 , Kaitlin E Hanken  4 , Julie C Lauffenburger  8 , Niteesh K Choudhry  8
Affiliations

Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: Rationale and design of a randomized controlled trial

Nancy Haff et al. Am Heart J. 2025 Jul.

Abstract

Background: Sodium-glucose cotransporter-2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) medications reduce the risk of cardiovascular and renal complications among patients with type 2 diabetes but are underutilized. There are numerous barriers to prescribing including insurance coverage, medication availability, comfort with prescribing, and diffusion of responsibility of prescribing across specialists. Methods are needed to support prescribing in primary care.

Methods: This was a pragmatic, randomized controlled trial testing interventions to increase appropriate SGLT2i and GLP-1RA prescribing. Primary care providers (PCPs) were randomized to 1 of 3 arms: (1) peer champion support (2) peer champion support and information on insurance coverage, or (3) usual care (no intervention). PCPs in both intervention arms received a welcome email and electronic health record (EHR) messages before visits with patients who had sub-optimally controlled diabetes and an indication for 1 of these medications. In the peer champion support only arm the EHR messages included prescribing tips. In the arm that provided peer champion support and information on insurance coverage, EHR messages contained information on medications in each class that would be most affordable for the patient based on their insurance coverage and offered support for prior authorizations if needed. The primary outcome was prescriptions for an SGLT2i or GLP-1RA medication, beginning 3 days before the targeted visit and continuing through 28 days, in each intervention arm compared to control.

Results: 191 primary care providers were included in the study. 1,389 patients had at least 1 visit scheduled with their PCP during the 6-month intervention period; of these 1,079 patients attended at least 1 of these visits and will be included in the primary outcome analysis. 66 providers (484 patients) received the peer champion intervention alone, 63 providers (446 patients) received the peer champion intervention and information on insurance coverage, and 62 providers (459 patients) received usual care. On average, patients were 66 years old, 46% were female, 61% were white, and 16% were Hispanic. There were small differences between groups with regards to patient sex, race, ethnicity, partner status, and percent with Medicare insurance.

Conclusions: These medication classes have the potential to reduce cardiovascular and kidney disease among patients with type 2 diabetes. This study tests interventions to support prescribing of these medications in primary care.

Clinical trial: Clinicaltrials.gov. Unique identifier: (NCT, Registered: NCT05463705).

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Dr. Choudhry serves as a consultant to Veracity Healthcare Analytics and holds equity in RxAnte and DecipherHealth; unrelated the current work, Dr. Choudhry has also received unrestricted grant funding payable to Brigham and Women’s Hospital from Humana. The remainder of the authors report no conflicts of interest.

References

    1. National Diabetes Statistics Report | Diabetes | CDC. November 29, 2023. Accessed January 5, 2024. https://www.cdc.gov/diabetes/data/statistics-report/index.html
    1. Li S, Wang J, Zhang B, Li X, Liu Y. Diabetes Mellitus and Cause-Specific Mortality: A Population-Based Study. Diabetes Metab J. 2019;43(3):319–341. doi: 10.4093/dmj.2018.0060 - DOI - PMC - PubMed
    1. Gurgle HE, White K, McAdam-Marx C. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Vasc Health Risk Manag. 2016;12:239–249. doi: 10.2147/VHRM.S83088 - DOI - PMC - PubMed
    1. Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet Lond Engl. 2021;398(10296):262–276. doi: 10.1016/S0140-6736(21)00536-5 - DOI - PubMed
    1. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2020;44(Supplement_1):S111–S124. doi: 10.2337/dc21-S009 - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data